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Abstract
Inflammasomes are multimeric protein complexes that respond to infection by recruitment and activation of the Caspase-1
(CASP1) protease. Activated CASP1 initiates immune defense by processing inflammatory cytokines and by causing a rapid
and lytic cell death called pyroptosis. Inflammasome formation is orchestrated by members of the nucleotide-binding
domain and leucine-rich repeat (NLR) or AIM2-like receptor (ALR) protein families. Certain NLRs and ALRs have been shown
to function as direct receptors for specific microbial ligands, such as flagellin or DNA, but the molecular mechanism
responsible for activation of most NLRs is still poorly understood. Here we determine the mechanism of activation of the
NLRP1B inflammasome in mice. NLRP1B, and its ortholog in rats, is activated by the lethal factor (LF) protease that is a key
virulence factor secreted by Bacillus anthracis, the causative agent of anthrax. LF was recently shown to cleave mouse and
rat NLRP1 directly. However, it is unclear if cleavage is sufficient for NLRP1 activation. Indeed, other LF-induced cellular
events have been suggested to play a role in NLRP1B activation. Surprisingly, we show that direct cleavage of NLRP1B is
sufficient to induce inflammasome activation in the absence of LF. Our results therefore rule out the need for other LF-
dependent cellular effects in activation of NLRP1B. We therefore propose that NLRP1 functions primarily as a sensor of
protease activity and thus could conceivably detect a broader spectrum of pathogens than just B. anthracis. By adding
proteolytic cleavage to the previously established ligand-receptor mechanism of NLR activation, our results illustrate the
remarkable flexibility with which the NLR architecture can be deployed for the purpose of pathogen-detection and host
defense.
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Introduction
Recognition of pathogens is an essential first step in the
initiation of protective host immune responses. Recognition of
pathogens has been shown to be mediated by several families of
germ-line encoded receptors that include the Toll-like receptors
(TLRs), Nucleotide-binding domain and Leucine-rich Repeat
containing proteins (NLRs), and RIG-I-like receptors (RLRs) [1].
Most TLRs, NLRs, and RLRs for which activation mechanisms
have been defined appear to function as ‘‘pattern recognition
receptors’’ [2] that directly bind to molecular structures called
pathogen-associated molecular patterns (PAMPs) that are broadly
conserved among many microbes. In addition to detection of
PAMPs, it has been previously proposed that the innate immune
system might also respond to ‘Patterns of Pathogenesis’, the
virulence-associated activities that pathogens utilize to invade or
manipulate their hosts [3]. Detection of pathogen-associated
activities might be a beneficial innate immune strategy, comple-
mentary to PAMP recognition, as it could allow the innate
immune system to discriminate pathogenic from non-pathogenic
microbes, and scale responses appropriately, despite the fact that
pathogenic and non-pathogenic microbes often share the same
PAMPs. However, few instances of a molecular mechanism by
which a pathogen-encoded activity could be detected have been
described in mammals. For example, a previous study showed how
pathogen-induced inhibition of protein synthesis by Legionella
pneumophila could be detected, leading to a specific cytokine
response [4,5]. Disruption of the actin cytoskeletal signaling by
bacterial toxins was also found to lead to a protective innate
immune response [6,7] Overall, however, there is still considerable
uncertainty as to whether or how ‘patterns of pathogenesis’ are
sensed by the innate immune system.
Anthrax lethal toxin (LeTx) is a critical virulence factor secreted
by Bacillus anthracis. LeTx is composed of two proteins: protective
antigen (PA) and lethal factor (LF). PA binds to anthrax toxin
receptors on host cells, and subsequently translocates the zinc-
metalloprotease, LF, into the cytosol. The canonical proteolytic
substrates of LF are mitogen-activated protein kinase kinases
(MAPKKs) 1–4 and 6–7 [8,9]. Cleavage by LF inactivates
MAPKKs and results in the disruption of signaling pathways
involved in host defense [10,11]. Macrophages from certain strains
of mice and rats respond to LeTx by undergoing a rapid and lytic
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form of Caspase-1 (CASP1)-dependent cell death called pyroptosis
[12–16]. The ability to undergo pyroptosis in response to LeTx
was genetically mapped to the Nlrp1b gene in mice [13], and
subsequently to the orthologous Nlrp1 gene in rats [16].
Importantly, mice harboring an allele of Nlrp1b that is responsive
to LeTx are protected from challenge with B. anthracis spores
[17,18]. This protection correlates with enhanced production of
IL-1b, recruitment of neutrophils to the site infection, and
decreased bacterial counts, and these processes depend on
expression of the interleukin-1 receptor [17,18]. Despite the
importance of NLRP1B in host defense against B. anthracis, the
mechanism of NLRP1B activation by LF remains unclear.
NLRP1B belongs to the NLR family of innate immune sensors
[19–21]. Several NLRs, including NLRP1, have been found to
assemble into oligomeric complexes, called ‘inflammasomes’ [22],
in response to a variety of infectious or noxious stimuli [21]. The
primary function of inflammasomes appears to be to form a
platform for activation of inflammatory caspase proteases, most
notably CASP1, but the molecular mechanism by which NLRs are
activated is poorly understood [21]. Although NLRP1 proteins
contain NBD and LRR domains, as do all other NLRs, the domain
organization of NLRP1 differs from other NLRs in two respects.
First, NLRP1 proteins contain a C-terminal Caspase Activation and
Recruitment Domain (CARD), whereas the CARDs in other NLRs
are usually N-terminal. The second unique feature of NLRP1
proteins is that they contain an unusual domain called the ‘function-
to-find’ (FIIND) domain [19]. The FIIND is located between the
LRRs and the C-terminal CARD, and was recently shown to
undergo an auto-proteolytic processing event that results in the C-
terminal CARD being cleaved from the rest of the NLRP1 protein
[23]. It is believed that the N- and C-terminal auto-processed
fragments of mature NLRP1B remain associated with each other
despite cleavage of the polypeptide chain [24]. The FIIND auto-
processing event occurs constitutively, prior to NLRP1B activation
by LF, but for reasons that remain unclear, is required for the ability
of NLRP1 to activate CASP1 [24,25].
Several inflammasomes have been suggested to be activated
upon direct binding to specific bacterial ligands. For example,
another NLR-family member, NAIP5, assembles into an inflam-
masome upon binding to flagellin, whereas the related NAIP2
inflammasome assembles upon binding to the inner rod proteins
from a variety of bacterial type III secretion systems [26,27]. A
direct receptor-ligand model also applies to the ALR-family AIM2
inflammasome, which is activated upon direct binding to
microbial DNA [28–31]. In contrast, certain inflammasomes,
notably the NLRP3 inflammasome, are believed not to bind
directly to bacterial ligands, but have instead been proposed to
respond to virally encoded ion channels [32], bacterial toxins, or
other cellular stresses, via indirect mechanisms [21]. However, the
molecular basis for how these stresses are sensed by NLRP3
remains unclear. By contrast, the molecular basis for indirect
pathogen recognition by plant NLRs has been well-established
[33,34]. For example, the plant NLR RPS2 has been shown to be
maintained in an inactive state by its association with RIN4, a host
protein that is targeted for degradation by a bacterial protease
[35,36]. RPS2 thus detects the activity of a bacterial protease
indirectly by monitoring or ‘guarding’ the integrity of the protease
substrate. Direct proteolytic cleavage of a plant NLR by a
pathogen-encoded protease has not been described.
NLRP1B responds to the protease activity of LF, as catalytically
inactive forms of LF do not activate NLRP1 [37,38]. This suggests
that NLRP1 does not recognize LF via simple receptor-ligand
binding, such as that occurs with the NAIP or AIM2 inflamma-
somes. Boyden and Dietrich initially hypothesized that LF could
cleave and activate NLRP1B [13], but evidence for this simple
model of NLRP1B activation was not provided. In fact, several
groups have demonstrated that the activity of the proteasome is
specifically required for this inflammasome and not for other
inflammasomes such as the NAIP5/NLRC4 inflammasome
[37,39]. In addition, inhibitors of the N-end rule degradation
pathway block NLRP1B activation but do not affect the ability of
LF to cleave MAPKKs [40]. In contrast to a model in which
NLRP1B is activated upon cleavage by LF, these observations
suggest that LF might activate NLRP1B by cleaving and
destabilizing a negative regulator of NLRP1B. This ‘indirect’
model resembles the activation of the certain NLRs, e.g., RPS2, in
plants. Recently, however, it was shown that the NLRP1 proteins
from Fischer rats and BALB/c mice can be directly cleaved near
their N-termini by LF [41,42]. Mutation of the cleavage site in rat
NLRP1 rendered NLRP1 resistant to cleavage by LF and also
prevented NLRP1 activation in response to LF. These results
suggest that cleavage of rat NLRP1 by LF is essential for NLRP1
activation, but it is difficult to rule out the possibility that mutation
of the cleavage site disrupted the fold of NLRP1, or rendered
NLRP1 non-functional for other reasons. In addition, the site at
which LF cleaves rat NLRP1 is not conserved in the mouse [42],
and moreover, the functional effects of mutating the mouse
cleavage site have not been assessed. Lastly, and most importantly,
existing studies have not ruled out the involvement of other LF-
dependent cellular events in NLRP1B activation, as cleavage of
NLRP1 was not shown to be sufficient for its activation.
Here, we present data that suggest that murine NLRP1B
requires LF-dependent cleavage for its activation. We further
demonstrate that cleavage is sufficient for NLRP1B inflammasome
activation in the absence of LF, which rules out a requirement for
cleavage of other LF substrates in activation of NLRP1B. Our
results provide evidence for a simple direct mechanism by which
an innate immune sensor detects a pathogen-encoded activity. In
addition, our results open the possibility that NLRP1 could
function as a direct cytosolic sensor of other pathogen-derived
proteases. More broadly, by adding direct proteolytic cleavage to
the existing ligand-receptor models for NLR activation, our results
Author Summary
Recognition of pathogens by the innate immune system is
necessary for initiating an appropriate immune response.
The innate immune system must distinguish pathogens
from abundant harmless microbes present within the host
and the environment, and scale the response appropri-
ately. It has been proposed that the host can respond
specifically to pathogens by monitoring common viru-
lence-associated activities, previously termed ‘‘patterns of
pathogenesis,’’ that are used by pathogens to survive and
replicate within their hosts. For example, pathogens can
manipulate host functions by delivering toxins into host
cells. In response, the host encodes dedicated cytosolic
sensors to detect these toxins, but the molecular basis for
how the sensors recognize the toxins is poorly understood.
Here we define the molecular mechanism by which a
mouse sensor, NLRP1B, directly recognizes the activity of a
bacterial toxin, lethal factor. Lethal factor is a protease
secreted by Bacillus anthracis, the causative agent of
anthrax. We show that anthrax lethal factor cleaves
NLRP1B and this cleavage event is both necessary and
sufficient for the activation of this sensor. Our findings
raise the possibility that NLRP1B could sense the activity of
other proteases encoded by diverse pathogens.
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also illustrate the remarkable adaptability of the NLR architecture
to function as pathogen-detectors in host defense.
Results
Mouse NLRP1B is cleaved by LF
The N-termini of mouse NLRP1B and rat NLRP1 were
recently reported to be cleaved by LF [41,42]. Interestingly, these
proteins do not exhibit much similarity in the region surrounding
the cleavage site (Fig. 1A), whereas the rest of the protein is highly
conserved between mice and rats (37% amino acid identity from
position 1–54 vs. 70% identity from residue 55 to the C-terminus).
The N-terminal fragment produced by LF is under 10 kDa and
appears to be unstable, making it difficult to detect by
conventional western blotting techniques in cell lysates. Thus, to
confirm that mouse NLRP1B is cleaved by LF, we augmented the
mass of the putative N-terminal fragment by 29 kDa by fusing full-
length NLRP1B to enhanced green fluorescent protein (EGFP)
and a hemagglutinin (HA) affinity-tag. We transfected this
construct into HEK 293T cells and then treated the cells with
LeTx. As reported previously, NLRP1B constitutively but only
partially auto-processes its FIIND domain in untreated cells,
resulting in a loss of 29 kDa from the C-terminus, and producing a
doublet of 140 kDa and 169 kDa that we will refer to as the
‘processed’ and ‘unprocessed’ forms of NLRP1B, respectively
(Fig. 1B and 1D) [24]. After LeTx addition, an N-terminal
fragment smaller than 37 kDa, but larger than EGFP-HA alone
(29 kDa), begins to accumulate inside cells. To distinguish LF-
dependent cleavage from auto-processing of the FIIND domain,
we will refer to the LF-dependent fragments as ‘cleaved’ (as
opposed to ‘processed’) NLRP1B (Fig. 1D). With kinetics
corresponding to the appearance of the cleaved N-terminal
fragment, the amount of the detectable uncleaved NLRP1B
decreased over time, consistent with removal of the N-terminal
tag. The LF-dependent cleavage of NLRP1B is not complete even
after 6 hours, and thus occurs much more slowly than the LF-
dependent cleavage of the MAP kinase kinase MEK2, a canonical
LF substrate, which appears complete within 2 hours (Fig. 1B).
To test if LF cleaves NLRP1B directly, without the GFP fusion,
we expressed an HA-tagged NLRP1B in 293T cells, immunopre-
cipitated NLRP1B, and then treated the purified protein with
recombinant LF in vitro. In the sample treated with LF, a fragment
smaller than 10 kDa is produced (Fig. 1C), suggesting that LF can
cleave mouse NLRP1B directly near the N-terminus, confirming
recent findings [42].
Cleavage is required for LF activation of NLRP1B
Even though the cleavage site in rat NLRP1 is not well-
conserved in mouse NLRP1B (Fig. 1A), two sequences can be
found in the N-terminus of mouse NLRP1B that partially fit the
previously established consensus specificity of LF [42] (Fig. S1A).
For clarity, we refer to the putative site nearest to the N-terminus
(cleavage after K38) as site-1, and the C-terminal site (cleavage
after K44) as site-2 (Fig. 1D and S1A). These two sites were also
identified as putative LF cleavage sites in a recent study [42], but
their functional importance was not addressed. We attempted to
generate cleavage resistant (CR) forms of NLRP1B by mutating
each site. We made a variety of amino acid substitutions at site-1
(CR1A-D) and site-2 (CR2A-C) (Fig. S1A), utilizing residues that
have previously been used to render MKK3 and MKK6 cleavage
resistant [43], or residues not found in LF consensus sites [44,45].
These mutants were transfected into 293T cells, and cells were
then treated with LeTx and assayed for cleavage. Mutation of
cleavage site-2 produced a cleavage-resistant form, despite the fact
that site-1 is intact in this mutant (Fig. 2A S1A–C). By contrast,
mutation of cleavage site-1 had little or no effect on NLRP1B
cleavage (Fig. S1A–C). When Casp1 and Il1b cDNA expression
vectors were cotransfected into this same 293T system, only CR2A
and CR2B were defective for induction of IL-1b processing into
p17 above the basal processing induced by CASP1 and NLRP1B
prior to stimulation (Fig. S1B–C). Thus, while confirming the
previous finding that both site-1 and site-2 of mouse NLRP1B can
be cleaved by LF [42], these results suggest that site-2 is the
predominant LF target within NLRP1B in cells.
We tested the ability of the CR2A NLRP1B mutant to form an
inflammasome capable of promoting pyroptosis. In these exper-
iments, we used immortalized macrophages from a C57BL/6 (B6)
mouse, because the endogenous B6 allele of NLRP1B is not
responsive to LeTx. As expected, immortalized B6 macrophages
transduced with a retroviral construct expressing the wild-type
129S1 allele of NLRP1B became sensitive to LeTx and underwent
pyroptosis, as assessed by release of cytosolic lactate dehydroge-
nase (LDH) into the supernatant (Fig. 2B). By contrast, transduc-
tion of B6 macrophages with the CR2A NLRP1B mutant did not
confer any measurable sensitivity to LeTx over the same time
period. This difference in responsiveness is not due to differences
in expression of the NLRP1B alleles (Fig. S2A). B6 cells harbor a
functional NAIP5 inflammasome; thus, as a further control, the
NLRP1B-transduced cells can be tested for inflammasome
responses to the cytosolic presence of flagellin. We therefore
delivered flagellin to the cytosol, via the protective antigen
translocation channel used by lethal factor, as a fusion to the
translocation signal in LF (dubbed ‘FlaTox’) [46] (Fig. 2B). Cells
transduced with wild-type and CR2A NLRP1B were equally
susceptible to FlaTox, indicating that they expressed functionally
equivalent levels of anthrax toxin receptor, CASP1, and down-
stream effectors required for pyroptosis. These data demonstrate
that the ability of mouse NLRP1B to respond to LF correlates with
the ability of LF to cleave NLRP1B at its N-terminus.
LF, expressed in the cytosol in the absence of PA, is
sufficient to activate NLRP1B
The ability of LF to cleave and activate NLRP1B has only been
tested in the presence of PA, since PA is typically required in order
to deliver LF to the cytosol. It is therefore unclear if PA is only
necessary for the translocation of LF in to the cytosol, or if it is also
required for NLRP1B activation. We decided to test the ability of
LF expression to induce pyroptosis and cytokine secretion in B6
and 129 immortalized macrophage-like cell lines with a Tet-On
inducible vector. We transduced these cell lines with a lentiviral
Tet-On GFP or LF expression vector and then treated the
transduced cells with doxycycline to induce GFP or LF expression.
LF expression was able to consistently induce pyroptosis in 129
(NLRP1B LeTx-responsive) cells but not B6 (NLRP1B LeTx-
nonresponsive) cells (Fig. S5A). Further addition of PA had no
additional effect on pyroptosis induction. Similar results were
obtained when IL-1b production was used to monitor NLRP1B
activation (Fig. S5B). These results show that the cytosolic
presence of LF is sufficient to activate NLRP1B and that
additional putative signals provided by PA pore formation are
not required.
Cleavage of NLRP1B is sufficient for inflammasome
activation
Together the above results suggest that mouse NLRP1B
requires direct cleavage in order to be activated by LF, but it is
difficult to rule out the formal possibility that the CR2A mutant is
Inflammasome Activation by NLRP1B Cleavage
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Figure 1. Murine NLRP1B from 129S1 mice is cleaved directly by LeTx. A) Protein sequence alignment of the N-terminal region of murine
NLRP1B (129S1 allele) and rat NLRP1 (Fischer/CDF allele) was determined by ClutalW with a BLOSUM series matrix. The LF cleavage motif and
cleavage site are identified in the rat allele by the bar and arrow above the rat sequence. B) GFP-HA-NLRP1B was transfected into HEK 293T cells and
then treated with 1 mg/ml LeTx over the indicate time points followed by immunoblotting (IB) for HA on non-boiled lysates, and boiled lysates when
probed with MEK2 and beta-actin antibodies. The arrow-head refers to the LeTx-dependent N-terminal cleavage fragment. C) HA-NLRP1B expressed
in 293T cells, immunoprecipitated (IP) with anti-HA beads, and treated with recombinant LF (rLF) for 2 h, followed by immunoblotting for HA. D)
Graphic representation of the GFP-HA-NLRP1B construct and annotated functional domains. The different forms of NLRP1B observed are shaded in
gray along with their predicted molecular weights, when immunoblotted with an anti-HA antibody.
doi:10.1371/journal.ppat.1003452.g001
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misfolded or is otherwise non-functional for reasons unrelated to
its resistance to cleavage by LF. Moreover, the above experiments
did not address whether cleavage alone is sufficient for activation
of NLRP1B. For example, LF may have other substrates that must
be cleaved in addition to NLRP1B, or LF itself could provide a
ligand-like signal for the cleaved NLRP1B receptor. To address
these possibilities, we replaced the predicted LF cleavage sites-1
and -2 in NLRP1B with a Tobacco Etch Virus (TEV) NIa
protease cleavage-site (Fig. S1A). TEV protease was selected
because it has no known endogenous substrates in mouse or
human cells. We transfected 293T cells with plasmids expressing
the wild-type and TEV-site forms of NLRP1B, along with
plasmids encoding CASP1, pro-IL-1b, and either LF or TEV
protease. As expected, wild-type NLRP1B was cleaved only in the
presence of LF, and this coincided with the generation of mature
IL-1b (Fig. 3A). Importantly, NLRP1B harboring a target
sequence for TEV protease in place of the LF target sequence at
site-2 (TEV-site2 NLRP1B) was cleaved efficiently by TEV
protease, and this cleavage was sufficient to promote IL-1b
processing. Consistent with the relatively low sequence specificity
of LF, the TEV-site2 NLRP1B protein was also cleaved by LF, but
this cleavage was inefficient as most of the NLRP1B remained
uncleaved, and IL-1b was not efficiently processed. Cleavage of
TEV-site1 also was sufficient to induce IL-1b processing, but this
occurred upon expression of either LF or TEV proteases.
Furthermore, the TEV-induced cleavage at site-1 produced a
fragment of NLRP1B that was smaller than the fragment
produced by LF expression (Fig. 3A and S1D). Consistent with
the mutagenesis experiments shown in Fig. 2, this observation may
indicate that LF prefers to cleave at site-2, which is still present in
the TEV-site1 NLRP1B protein. Taken together, these results
suggests that cleavage of NLRP1B at either site-1 or site-2 is
sufficient to induce inflammasome activation independently of
other LF-dependent cellular effects.
We also confirmed that cleavage of NLRP1B is sufficient to
induce pyroptosis in macrophages cell lines. We transduced
immortalized B6 macrophages with two different retroviral
vectors, one expressing GFP-NLRP1B and the other expressing
TEV protease with an IRES-Thy1.1 expression marker. If
cleavage is sufficient to activate NLRP1B, it is expected that only
cells expressing both components would undergo pyroptosis and
therefore be underrepresented in the live population of cells. We
analyzed the percentage of cells that contained both retroviruses
by measuring THY1.1 surface-expression and GFP fluorescence
by flow cytometry. As expected, an underrepresentation of the
THY1.1 and GFP double-positive population was specifically seen
in cells transduced with TEV and TEVsite2-NLRP1B, while the
frequency of THY1.1+ cells was similar in cells that where
negative for both forms of NLRP1B (Fig. 3B).
To further confirm that cleavage of NLRP1B is sufficient for
inflammasome activation, we transduced RAW 264.7 cells with
retroviral vectors encoding various NLRP1B alleles, as well as a
lentiviral Tet-On vector that inducibly expresses GFP, TEV-
protease or LF after exposure of cells to doxycycline. In this
system, TEV expression induced high levels of LDH release only
for cells expressing TEVsite2-NLRP1B. As expected, since RAW
cells express an endogenous functional allele of NLRP1B, LF
induced pyroptotic lysis of cells expressing either wild-type or
TEVsite2-NLRP1B (Fig. 3C). The percent LDH release was
generally consistent with the percentage of cells that expressed
both constructs (Fig. S2B). These data demonstrate that cleavage
of NLRP1B is sufficient to activate this inflammasome in
macrophages and cause pyroptosis.
No apparent role for the N-terminal NLRP1B cleavage
fragment
We next tested whether the N-terminal fragment generated by
cleavage of NLRP1B by LF at site-2 must be present along with
the corresponding C-terminal fragment. We generated a construct
to express a ‘pre-cleaved’ C-terminal fragment by deleting residues
1–44 of full-length NLRP1B and replacing amino acid 45 (leucine)
with an initiator methionine. The resulting C-terminal fragment
contains all known functional domains of NLRP1B (Fig. 1D). In
the 293T cell system, high levels of spontaneous IL-1b cleavage
was observed upon expression of the precleaved NLRP1B. The
activity of pre-cleaved NLRP1B was comparable to that of a
DLRR mutant, a form of NLRP1B that is known to be
constitutively active (Fig. 3D and S3C) [47]. When the N-terminal
fragment (amino acids 1–44) was coexpressed with the precleaved
C-terminal fragment, no change in the amount of IL-1b processing
Figure 2. Mouse NLRP1B cleavage by LF is required for inflammasome activation. A) Both WT and CR2A GFP-HA-NLRP1B were transfected
into 293T cells and then treated with LeTx for the indicated times, and cleavage was monitored by immunoblotting with indicated antibodies. B)
Immortalized macrophages from a C57BL6 mouse were transduced with both forms of GFP-HA-NLRP1B and then treated with LeTx or LFn-Fla+PA
(FlaTox). Pyroptosis was assayed by LDH release and normalized to complete detergent lysis. Error bars represent plus and minus one standard
deviation from the mean.
doi:10.1371/journal.ppat.1003452.g002
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was observed (Fig. S3B), suggesting it is neither necessary nor
inhibitory when expressed in trans. For all of these experiments, the
differences in the amount of IL-1b cleavage were not explained by
differences in expression of NLRP1B (Fig. S3A–C).
Proteasome inhibitors and FIIND processing do not affect
LF-dependent cleavage
NLRP1B inflammasome activation can be blocked by protea-
some inhibitors, an effect that is observed with multiple inhibitors
and is specific to the NLRP1B inflammasome and not the NAIP/
NLRC4 inflammasome [37,39]. The mechanism by which
proteasome inhibitors affect NLRP1B inflammasome activation
is not currently known. Therefore, we tested whether the
proteasome inhibitor MG132 blocked NLRP1B cleavage. In the
293T system, an equivalent amount of cleaved of NLRP1B
occurred in the presence of MG132 and its vehicle (Fig. 4A),
suggesting NLRP1B cleavage is not the step at which MG132
interferes with NLRP1B activation (Fig. S4A).
The FIIND of NLRP1B contains a ZU-5/UPA-like domain that
can auto-process, and this auto-processing is required for NLRP1B
activation [23,24]. We tested if auto-processing at the FIIND region
is prerequisite for N-terminal cleavage by LF. We tested the FIIND
mutant S984A, which cannot auto-process, and found it to be
indistinguishably sensitive to LeTx cleavage as wild-type NLRP1B
(Fig. 4B). Thus FIIND auto-processing appears to be required for a
downstream step in NLRP1B activation (Fig. S4B), and is not
required for NLRP1B to be sensitive to LeTx cleavage.
Discussion
Activation of the NLRP1B inflammasome by LeTx is an
important resistance mechanism during Bacillus anthracis infections
in mice [17,18]. However the question of how NLRP1B senses the
Figure 3. Cleavage of NLRP1B is sufficient to promote inflammasome activation. A) 293T cells were transfected with WT, TEV-site2 or TEV-
site1 GFP-HA-NLRP1B along with empty vector, TEV expression vector, or a LF expression plasmids. In all conditions cells were also co-transfected
with Casp1 and Il1b expression vectors. Cleavage of GFP-HA-NLRP1B and IL-1b was determined 24 h post transfection. B) Immortalized B6
macrophages were transduced with a retrovirus encoding the indicated GFP-HA-NLRP1B form followed by a sequential transduction with a TEV-
expression retrovirus co-expressing THY1.1. Percent transduction was determined by measuring expression of the respective retroviral integration
markers (GFP and anti-THY1.1-PE-Cy7) by flow cytometry, and are expressed in relative fluorescent units (RFU). The numbers within each quadrant
represent the percentage of live cells within the respective quadrant. C) RAW264.7 macrophages were transduced with GFP-HA-NLRP1B and a Tet-On
construct expressing the indicated gene. Cells were treated with 5 mg/ml doxycycline for 20 h and supernatants were assayed for LDH release. D)
293T cells were transfected with empty vector, FL-NLRP1B-HA, the truncated NLRP1B-HA, or DLRR HA-NLRP1B, along with Casp1 and Il1b and assayed
by immunoblotting.
doi:10.1371/journal.ppat.1003452.g003
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PLOS Pathogens | www.plospathogens.org 6 June 2013 | Volume 9 | Issue 6 | e1003452
protease activity of LF remains unresolved. Here we investigated
the molecular mechanism by which the protease activity of B.
anthracis lethal toxin could be detected by NLRP1B. Our studies
provide a clear molecular mechanism for how a pathogen-encoded
activity (or ‘pattern of pathogenesis’ [3]) can be sensed by the
innate immune system.
Two recent studies by Moayeri and colleagues provided a
considerable advance in our understanding of NLRP1B activation
by LeTx [41,42]. These two studies showed that both rat and
mouse NLRP1 can be cleaved near the N-terminus by LF, and
that mutation of the cleavage site abolished responsiveness of rat
NLRP1 to LF. While these findings strongly suggest that direct
cleavage of rat NLRP1 could be its mechanism of activation, the
functional role of cleavage of mouse NLRP1B was not addressed,
and it is also possible that mutation of the cleavage site blocked
activation of rat NLRP1 by affecting the folding or assembly of
NLRP1. Most significantly, the question of whether cleavage of
NLRP1B was sufficient for its activation has not been addressed.
This question is especially important to address because LT has
been shown to have complex effects on cells, including disruption
of MAP kinase signaling [43,48,49], that could conceivably play a
role in NLRP1B activation. Moreover, several other cellular
functions, such as proteasome activity and N-end rule degradation
pathways, have been implicated in NLRP1B activation [37,39,40].
Therefore, to demonstrate that cleavage of NLRP1B is sufficient to
induce inflammasome activation, we engineered an allele of
NLRP1B that could be activated by the heterologous TEV
protease. This protease is not known to have endogenous
substrates in mouse or human cells, so is likely to exert its effects
solely via direct cleavage of the engineered NLRP1B protein.
Indeed, the TEV protease did not activate NLRP1B unless
NLRP1B contained a site that could be cleaved by TEV (Fig. 3A).
Recent data have suggested that mouse NLRP1B can be cleaved
at two distinct sites by LF [42], but our cleavage site mutants and
TEV-site forms of the receptor are most consistent with site-2
(cleavage between residues 44–45) being the predominant cleavage
site. Interestingly, this site coincides with the same amino acid
position as the LF cleavage site in rat NLRP1, even though the
sequences of the two sites are not conserved (Fig. 1A). The low
degree of target sequence specificity exhibited by LF may have
allowed the sequence of the cleavage site in NLRP1 to diverge
without losing responsiveness to LF. The position within NLRP1
at which LF cleaves may be determined in part by interactions
between LF and regions of NLRP1 outside of the cleavage site.
Indeed, similar non-cleavage-site interactions appear to control the
specificity of LF for its other known substrates, the MAPKKs
[9,10]. The divergence of the amino acid sequence of the N-
terminus of NLRP1B is interesting given the high degree of
conservation in the rest of the protein. This divergence may be due
to random drift of a structurally unconstrained domain, or
alternatively, the divergence may reflect evolutionary pressure
for NLRP1 to be recognized by other pathogen-encoded
proteases. Notably, our data suggest that cleavage outside of the
primary LF target site (e.g., at site-1) can also activate NLRP1B
(Fig. 3A), although it is unclear if LF can cleave and activate
NLRP1B at this position. In addition, our data suggest that
cleavage of NLRP1B does not necessarily have to be complete to
be sufficient to permit inflammasome assembly and CASP1
activation. Taken together, these observations suggest that
NLRP1B could be responsive to proteases from other pathogens
even if these proteases cleave NLRP1B at different sites with low
efficiency. Indeed, countless pathogens, including bacteria, viruses
and parasites, depend on cytosolically-localized proteases for
virulence [50–53]. Therefore the presence of cytosolic proteases
could be considered a ‘pattern of pathogenesis’ [3], that could be
detected by NLRP1 proteins to allow the innate immune system to
discriminate pathogenic and harmless microbes. The divergence
of rat and mouse NLRP1 may thus reflect evolution under the
selective pressure imposed by distinct sets of pathogens in the two
different rodents species. It will be interesting to determine if other
proteases can activate rodent NLRP1s.
The detection of protease activity by NLRP1B represents a
fundamentally distinct mode of pathogen recognition in verte-
brates as compared to the classic mode of direct recognition of
PAMPs observed with most innate immune receptors of the TLR,
NLR and RLR families. The N-terminus of NLRP1B appears to
function to detect LF activity in a manner analogous to the ‘decoy’
model [54], which has been previously proposed to explain
detection of certain pathogen effectors by plant NLRs. The
proteolytic mechanism by which NLRP1B is activated represents
one of the few examples in mammals in which a molecular
mechanism has been established for how an innate immune sensor
can respond to a pathogen-encoded activity.
It is currently unknown how cleavage of the N-terminus results
in structural changes that lead to NLRP1B activation. A simple
model is that the N-terminus of NLRP1B mediates an auto-
inhibitory intramolecular interaction, perhaps via an interaction
with the LRR domain, which is known also to be required for
auto-inhibition of NLRP1B (Fig. 3D) [47]. An alternative model
that is not excluded by our data is that the removal of the original
N-terminus allows the neo-N-terminus to provide a positive signal
to activate NLRP1B. More complicated models involving inter-
actions with other proteins can also be envisaged. We did not
observe an inhibitory role of the N-terminal fragment when
expressed in trans (Fig. S3). This suggests that the N-terminus is
necessary to maintain NLRP1B in a conformation that is inactive,
but can only do so when the N-terminus is covalently attached to
the rest of NLRP1B.
Figure 4. Proteasome inhibition and FIIND-processing do not
affect NLRP1B cleavage by LF. A) 293T cells expressing GFP-HA-
NLRP1B were co-treated with 1 mg/ml LeTx and 10 mM MG132
(proteasome inhibitor) or the DMSO vehicle and assayed for cleavage.
B) Cleavage susceptibility of WT and S984A (FIIND mutant) GFP-HA-
NLRP1B was determined in 293T cells at the indicated time points.
doi:10.1371/journal.ppat.1003452.g004
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In addition to proteolytic cleavage by LF, additional layers of
NLRP1B regulation appear to exist. For example, FIIND auto-
processing is required for NLRP1B activity, for reasons that
remain poorly understood [24]. Since we found that FIIND auto-
processing mutants are still cleaved by LF, the role of FIIND auto-
processing appears not to be to render NLRP1B susceptible to
cleavage by LF. Further complexities in NLRP1B activation are
also suggested by the observation that proteasome and N-end rule
pathway inhibitors appear to specifically prevent NLRP1B-
dependent CASP1 activation [37,39,40]. Even though previous
studies have shown that proteasome inhibitors do not block
cleavage of MAPKK by LF [37,39], we tested if proteasome
inhibition might affect cleavage of NLRP1B, which appears to be
a less optimal substrate than the MAPKKs. However, we observed
no effect of the proteasome inhibitor MG132 on the ability of LF
to cleave NLRP1B. Thus it remains unclear how this inhibitor
specifically blocks the NLRP1B inflammasome and not other
inflammasomes. Models that attempt to explain the mechanism of
NLRP1B are further complicated by other unique features of
NLRP1B. For example, ATP binding to the NBD of NLRP1B is
not necessary for inflammasome activation, and mutants of
NLRP1B that are unable to bind ATP are actually constitutively
active [55]. This is contrary to what is known for other
mammalian NLRs, where ATP binding appears to be required
for oligomerization and downstream signaling [21]. Furthermore,
gross truncations of NLRP1B can also lead to constitutively active
forms of NLRP1B that contain only the very C-terminal CARD
and a portion of the FIIND [47]. Thus, other disturbances, by
proteolysis or by other means, to the overall structure of NLRP1B
could lead to loss of the conformation that mediates auto-
inhibition.
In general, the molecular conformational changes that occur in
NLRs as they transition from an inactive to an active state are
poorly understood. Thus, our studies of NLRP1B provide an
important point of comparison that helps us to develop a broader
understanding of the NLR class of innate immune sensors and the
mechanisms of their activation.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Animal Care and Use Committee at the University
of California, Berkeley (MAUP #: R301-0313BRC).
Plasmids and constructs
HA-NLRP1B was amplified from a Nlrp1b (DQ117584.1)
cDNA (gift of E. Boyden and B. Dietrich, Harvard Medical
School) with primers 1–2 and cloned into pCMSCV-IRES-hCD4
using the XhoI and NotI restriction sites (Fig. S5). A construct for
expression a GFP-HA-NLRP1B fusion was created by amplifying
HA-NLRP1B with primers 3–4 and cloning the resulting PCR
product into MSCV downstream of and in-frame with GFP using
NotI and SalI sites. TEV expression constructs were created by
amplifying a His6-TEV ORF with the primers 7–9 and 8–9 into
pCMSCV-IRES-Thy1.1 and pFG12-rtTA-IRES-Thy1.1, respec-
tively. LF was similarly cloned into the same vectors as TEV, but
with the primers 10–11 and 12–13 using a template provided by
Bryan Krantz (UC Berkeley). Mutagenesis of Nlrp1b was
performed using Quickchange (Stratagene/Agilent), but modified
by substituting the Pfu polymerase for PrimeSTAR HS (TA-
KARA/Clonetech). The primers used are listed in Fig. S6.
Cell culture
HEK293T (ATCC) cells were grown in complete media (DMEM,
10%FBS, 100 U/ml Penicillin, 100 mg/ml Streptomycin, and
supplemented with 2 mM L-glutamine). RAW 264.7 and immor-
talized B6 macrophages were grown in complete media (RPMI
1640, 10%FBS, 100 U/ml Penicillin, 100 mg/ml Streptomycin).
DNA transient transfections
HEK 293T cells were seeded the day prior to transfection at a
density of 1.56105 cells/well in a 24-well plate with complete
media. DNA complexes were made with Lipofectamine 2000
(Invitrogen) according to manufactures instructions and overlaid
on cells for 24–36 hours.
Western blots
Cells were lysed in RIPA buffer supplemented with 1 mM
PMSF and 16X Complete Protease Inhibitor Cocktail (Roche).
Lysates were spun down at max speed at 4C for 20 min and
supernatants were mixed with 66 Laemmli sample buffer. To
detect full length NLRP1B, lysates were incubated at room
temperature prior to SDS-PAGE. To analyze all other proteins,
including the N-terminally cleaved form of NLRP1B, samples
were boiled for 10 min prior to separation. SDS-PAGE was
performed with Novex BisTris gel system according to manufac-
turer instructions (Invitrogen). Separated proteins were transferred
on to Immobilon-FL PVDF membranes. Membranes were
blocked with Odyssey blocking buffer (Licor). The following
antibodies were used for the following antigens: HA mAB 3F10
(Roche), MEK-2 SC-13115 (Santa Cruz), Beta Actin SC-4778
(Santa Cruz), IL-1B AF-401-NA (R&D systems). Secondary
antibodies anti-rat, mouse and goat were all conjugated to Alexa
Flour-680 (Invitrogen).
Immunoprecipitation and LF in vitro cleavage assay
Transfected cells were lysed in a non-denaturing buffer (1% NP-
40, 137 mM NaCl, 2 mM EDTA, 20 mM Tris pH 8 supple-
mented with protease inhibitors). Cleared lysates were bound to
EZview Red Anti-HA Affinity Gel (Sigma) washed four times with
lysis buffer, once in LF cleavage buffer (10 mM NaCl, 5 uM
ZnSO4, 10 mM HEPES pH 7.4), and resuspended back into
cleavage buffer. One microgram of recombinant LF was added to
immunoprecipitated NLRP1B and incubated at 37uC for 2 hours,
and analyzed by western blotting as described above.
Cytotoxicity/Pyroptosis assay and IL-1b secretion
Macrophages were seeded one day prior to treatment in a
96well plate at 56104 cell/well in RPMI media without phenol
red. The next day cells were treated with LeTx 1 mg/ml, FlaTox
1 mg/ml [46], or doxycycline at 5 mg/ml in ethanol for the
indicated time, and spun down at 4006g. For IL-1b release cells
were pretreated/cotreated with 1 mg/ml of Pam3CSK4. Super-
natants were removed and assayed for LDH and IL-1b release as
described previously [56].
Supporting Information
Figure S1 Predicted LF cleavage-site mutation compar-
ison. A) LF cleavage-site1 predicts cleavage between K38-39 and
the motif surrounding this site was progressively mutated away
from the consensus motif. Cleavage-site 2 predicts cleavage
between K44 and L45, and this site was muted only at residues
immediately surrounding the site. TEV cleavage sites were
introduced to produce cleavage after residue 38 for site-1, and
residue 44 for site-2. B) Cleavage site-1 mutant series (CR1A-D))
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and CR2A were transfected into 293T cells and treated with 1 mg/
ml LeTx for 4 h, analyzed by western blotting with the indicated
antibodies. The bottom blot was done in the presence of Casp1 to
determine the extent of IL-1b processing. C) WT, CR1D, CR2A-
C GFP-HA-NLRP1B were transfected into 293T cells and treated
with 1 mg/ml LeTx for the indicated time points and cleavage and
IL-1b processing was assayed by western blotting. D) WT and
TEV-site1 GFP-HANLRP1B were cotransfected with TEV or
empty expression vector into 293T cells. Thirty-six hours post
transfection cells were treated with LeTx for 4 h, then lysed and
analyzed by immunoblotting with an anti-HA antibody.
(TIF)
Figure S2 Transduction efficiency is the same in
macrophage cell lines. A) Immortalized B6 macrophages
were transduced with WT and CR2A GFP-HA-NLRP1B.
Expression and cleavage of each NLRP1B was determined by
western blotting. Glycine (5 mM) was added 1 hour post the
addition of LeTx to block lysis of cells in the 2 h and 3 h time
points. B) Percent transduction of RAW 264.7 macrophages was
determined by measuring THY1.1 surface expression for the Tet-
On vector, and GFP expression for the NLRP1B vector under
non-inducing conditions by flow cytometry. GFP and anti-
THY1.1-PE-Cy7 fluorescence are expressed in relative fluores-
cence units (RFU). The numbers within each quadrant represent
the percentage of live cells within the respective quadrant.
(EPS)
Figure S3 NLRP1B’s N-terminal fragment has no role in
inflammasome activation when expressed in trans. A)
Expression of FL, precleaved and DLRR mutants of NLRP1B
were determined by anti-HA immunoblotting. B) 293T cells were
cotransfected with C-terminally HA tagged WT or precleaved
NLRP1B along with Casp1 and Il1b expression constructs. The N-
terminal fragment (residues 1–44) fused to GFP-HA was co-
transfected with the C-terminal fragments and assayed for IL-1b
24 h post-transfection. C) Processing of IL-1b in 293T cells was
determined to be dependent on NLRP1B expression and the
catalytic activity of CASP1.
(TIF)
Figure S4 MG132 blocks NLRP1B activity and FIIND
processing is required in 293T cells. A) IL-1b processing
was analyzed in 293T cells expressing GFP-HA-NLRP1B, Casp1,
Il1b and treated with MG132 (proteasome inhibitor) and LeTx for
the indicated time points. B) The necessity of FIIND domain
processing for NLRP1B activation in 293T cells was determined
by measuring IL-1b processing in cells expressing GFP-HA-
NLRP1B, Casp1, Il1b, after treatment with LeTx for the indicated
time points.
(TIF)
Figure S5 LF expression is sufficient to induce pyrop-
tosis and IL-1b in 129 macrophages. A,B) Immortalized
C57BL/6 (B6) and 129 macrophages were transduced with a Tet-
On construct expressing the GFP or LF. Cells were treated with
1 mg/ml Pam3CSK4, 5 mg/ml doxycycline and 1 mg/ml PA for
20 h and supernatants were assayed for LDH release (A) and IL-
1b release (B) into the supernatant. Cells were also treated with
1 mg/ml LeTx and 5 mg/ml FlaTox for 4 h prior supernatant
collection. Error bars represent plus and minus one standard
deviation from the mean. ND stands for not determined.
(EPS)
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